Replimune Group, Inc. (REPL)
REPLNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$22.26
+0.6400 (+2.96%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.11bn
- P/E
- –
- EPS, last 4 quarters
- $-2.79
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.50 to $21.91
- Average volume
- 2.46m
- Previous close
- $21.62
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $23.17, +4.1% from here
Earnings
next estimate $-0.5700Next report
Dec 2025
+9.4%
Mar 2026
-4.1%
Jun 2026
0.0%
Sep 2026
+22.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$71.87m | -$73.34m | -$68.25m | -$56.28m |
| Net income | -$70.93m | -$73.22m | -$69.77m | -$57.12m |
News
8 latest- Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to TradeZacks · Nov 2, 2026
- Replimune Group Consensus Price Target Increased by 14.78% to $22.44Fintel · Nov 2, 2026
- Replimune: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Oct 28, 2026
- Replimune (REPL) Q2 2027 Earnings Call TranscriptThe Motley Fool · Oct 28, 2026
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% RTTNews · Oct 28, 2026
- Replimune Group, Inc. Reports Fiscal Second Quarter 2027 Financial Results and TUDRIQEV LaunchFintel · Oct 28, 2026
- Replimune Posts Narrower Loss In Q2 RTTNews · Oct 28, 2026
- Notable Tuesday Option Activity: MCY, INSM, REPLBNK Invest · Oct 27, 2026
The company
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- replimune.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.